Cinclus Pharma Cash Flow-to-Debt Ratio
Cinclus Pharma cash flow-to-debt ratio. Cinclus Pharma (CINPHA) has a Cash Flow-to-Debt Ratio of -0.39x as of June 2026, meaning its operating cash flow of Skr-86.19 Million could theoretically repay 0% of its total liabilities (Skr221.84 Million) in one year. See CINPHA FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cinclus Pharma (2022–2025)
Cash flow-to-debt ratio of Cinclus Pharma from 2022 to 2025. Historical debt coverage capacity for Cinclus Pharma across 4 annual periods. Check cash flow reinvestment rate of Cinclus Pharma to assess the company's total reinvestment commitment from operating cash flow.
Cinclus Pharma Cash Flow-to-Debt Ratio by Year (2022–2025)
Cinclus Pharma cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Cinclus Pharma. For the full cash flow conversion analysis, see Cinclus Pharma cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.42x | Skr-74.65 Million | Skr177.16 Million | ▲ +89.2% |
| 2024 | -3.90x | Skr-178.37 Million | Skr45.68 Million | ▼ -219.6% |
| 2023 | -1.22x | Skr-209.19 Million | Skr171.21 Million | ▲ +62.5% |
| 2022 | -3.26x | Skr-192.08 Million | Skr58.90 Million | — |